Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)

Paweł Golik; Katarzyna Tońska

eISSN: 2719-3209
ISSN: 0023-2157

Klinika Oczna / Acta Ophthalmologica Polonica

Current issue Archive Videos Articles in press About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures Supplements Instructions for authors Publication charge

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2012
vol. 114

Send email

Copy url:

Review paper

Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)

Paweł Golik

¹

,

Katarzyna Tońska

¹

Instytut Genetyki i Biotechnologii Wydziału Biologii Uniwersytetu Warszawskiego

Klinika Oczna 2012, 114 (1)

Online publish date: 2012/03/29

Article file

- 17 GOLIK_POROWNANIE.pdf [0.29 MB]

Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Golik P, Tońska K. Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor). Klinika Oczna / Acta Ophthalmologica Polonica. 2012;114(1):79-83.

APA

Golik, P.,  & Tońska, K. (2012). Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor). Klinika Oczna / Acta Ophthalmologica Polonica, 114(1), 79-83.

Chicago

Golik, Paweł,  and Katarzyna Tońska. 2012. "Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)". Klinika Oczna / Acta Ophthalmologica Polonica 114 (1): 79-83.

Harvard

Golik, P.,  and Tońska, K. (2012). Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor). Klinika Oczna / Acta Ophthalmologica Polonica, 114(1), pp.79-83.

MLA

Golik, Paweł et al. "Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)." Klinika Oczna / Acta Ophthalmologica Polonica, vol. 114, no. 1, 2012, pp. 79-83.

Vancouver

Golik P, Tońska K. Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor). Klinika Oczna / Acta Ophthalmologica Polonica. 2012;114(1):79-83.

Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)

Paweł Golik 1 , Katarzyna Tońska 1

Paweł Golik

¹

,

Katarzyna Tońska

¹